샘플 요청 목록

 카트 문의
시장보고서
상품코드
1737274

세계의 승모판 질환 치료제 시장

Mitral Valve Disease Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 376 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

승모판 질환 치료제 세계 시장은 2030년까지 6억 8,900만 달러에 달할 전망

2024년에 6억 2,490만 달러로 추정되는 승모판 질환 치료제 세계 시장은 분석 기간인 2024-2030년에 CAGR 1.6%로 성장하여 2030년에는 6억 8,900만 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 β 차단제는 CAGR 1.4%를 기록하며 분석 기간 종료시에는 3억 790만 달러에 달할 것으로 예측됩니다. 이뇨제 부문의 성장률은 분석 기간 동안 CAGR 1.3%로 추정됩니다.

미국 시장은 1억 7,030만 달러로 추정, 중국은 CAGR 3.1%로 성장 예측

미국의 승모판 질환 치료제 시장은 2024년에 1억 7,030만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 1억 2,600만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 3.1%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 0.7%와 1.4%로 예측됩니다. 유럽에서는 독일이 CAGR 약 0.9%로 성장할 것으로 예측됩니다.

세계의 승모판 질환 치료제 시장 - 주요 동향과 촉진요인 정리

승모판 질환이 심혈관 치료제의 임상적, 상업적 주목을 받는 이유는 무엇일까?

승모판막 폐쇄부전증(MR) 및 승모판막 협착증(MS)과 같은 질환을 포함한 승모판 질환은 전 세계 심혈관질환의 이환율과 사망률, 특히 고령화 사회의 주요 원인이 되고 있습니다. 좌심방과 좌심실 사이의 혈류를 조절하는 승모판막의 기능 장애가 특징인 이 질환은 치료하지 않으면 역류, 압력 부하, 폐고혈압, 심방세동, 그리고 결국 심부전으로 이어집니다. 진행성 및 복잡한 병태생리를 고려할 때, 돌이킬 수 없는 심장 리모델링과 사망을 예방하기 위해서는 조기 진단과 적절한 개입이 필수적입니다.

인구 고령화, 류마티스성 심장질환의 유행, 조기 심장중재술로 인한 생존율 향상 등으로 인해 승모판 질환의 부담은 선진국과 개발도상국 모두에서 급증하고 있습니다. 역사적으로 진단과 치료가 미흡했던 승모판 질환은 심초음파 검사를 통한 스크리닝의 증가, 순환기 전문의의 인식 개선, 최소침습적 치료의 기술적 진보로 인해 다시 주목받고 있습니다. 이에 따라 수술적 치료, 경카테터 판막 치료, 약리학적 관리, 장치를 이용한 중재 등 다양한 치료 시장이 확대되고 있습니다.

경카테터 삽입술과 수술적 진보가 치료의 전망을 어떻게 바꾸고 있는가?

승모판 질환의 치료 패러다임은 전통적인 개심술에서 덜 침습적인 경카테터 접근법으로 전환되고 있습니다. 수술적 승모판막 성형술이나 판막 치환술은 여전히 젊고 건강한 환자에게는 여전히 표준이지만, 고령자나 고위험군 환자들은 이러한 수술에 적합하지 않은 경우가 많습니다. 이러한 상황에서 MitraClip(Abbott) 및 PASCAL 시스템(Edwards Lifesciences)과 같은 경피적 카테터 승모판막 복원술(TMVR) 시스템은 기능적 MR 및 퇴행성 MR에 대한 입증된 경피적 대안을 제공함으로써 관리의 혁명을 가져왔습니다.

이러한 시스템은 대퇴동맥을 통해 카테터를 삽입하여 전단부 관상동맥중재술이나 고리형성술을 가능하게 하여 입원 시간, 시술 위험 및 회복 기간을 크게 단축시켰습니다. 동시에 ACE 억제제, 베타차단제, 이뇨제로 구성된 약물요법은 증상 완화 및 심부전 합병증 관리를 위해 여전히 중요합니다. 로봇 보조 판막 복원술, 최소침습적 흉강경 수술, 첨단 영상 유도를 통한 수술 중 계획과 같은 수술적 혁신은 수술의 정확성과 환자 결과를 더욱 향상시키고 있습니다. 승모판막 성형술과 좌심방 부속기 폐쇄술, 폐정맥 격리술, 판막하 중재술을 결합한 차세대 장치에 대한 임상시험이 진행 중입니다.

승모판막 치료의 세계 보급을 주도하는 환자층, 치료 환경, 시장은?

승모판 질환 치료의 중심 환자군은 65세 이상이며, 고혈압, 심방세동, 당뇨병 등 여러 동반 질환을 앓고 있는 경우가 많습니다. 외래 순환기 클리닉과 일차 진료에서 심혈관 검진율이 증가함에 따라 무증상 또는 잠재적 MR의 발견이 증가하고 있습니다. 중재적 심장 전문의, 심장외과 전문의, 영상 진단 전문가로 구성된 병원 기반 심장팀은 심초음파를 통한 심전도 등급 평가 및 위험도 분류 도구에 기반한 치료 방침 결정에 중요한 역할을 하고 있습니다.

북미와 서유럽은 유리한 상환 제도, 잘 정비된 심장 인프라, 빠른 규제 승인으로 인해 TMVR 기술 채택을 주도하고 있습니다. 아시아태평양, 특히 일본과 중국은 노인 인구 증가, 전문 심장 치료 접근성 향상, 의료기기 혁신에 대한 투자로 인해 빠르게 성장하고 있습니다. 라틴아메리카, 동유럽, 중동은 신흥 시장으로 수술적 치료가 여전히 주류를 이루고 있지만, 카테터 치료에 대한 관심이 높아지면서 치료 선호도가 변화하고 있습니다.

승모판 질환 치료제 시장의 장기적인 성장과 혁신의 원동력은 무엇인가?

승모판 질환 치료제 시장의 성장은 인구통계학적 추세, 기기 혁신, 임상 가이드라인의 업데이트, 결과 기반 의료 모델의 융합에 의해 촉진되고 있습니다. 심혈관 치료가 점점 더 개인화됨에 따라 덜 침습적이고, 영상으로 유도되는 환자 맞춤형 판막 복원 솔루션에 대한 수요가 가속화되고 있습니다. 멀티모달 영상 진단, 위험 예측을 위한 머신러닝, 치료 알고리즘에 실제 데이터를 통합하여 진단 및 시술 계획의 정확성을 높이고 있습니다.

TMVR 시술에 대한 지불자의 지원, TAVR(경피적 대동맥판막 치환술) 인프라의 승모판막 적용 확대, 그리고 전문 분야를 넘어선 협력은 보다 폭넓은 채택 가능성을 이끌어내고 있습니다. 또한, 혈관 복구 시스템, 고리형 링, 고분자 인공 판막과 같은 파이프라인 기술은 치료 툴킷을 다양화하고 있습니다. 혈역학적 안정화와 기계적 교정을 결합한 의약품 및 기기의 하이브리드 접근법은 심부전 관련 MR 관리에 있어 관심을 받고 있습니다.

구조적 심장 질환 치료가 수술의 영역을 넘어 진화함에 따라 승모판막 치료제는 심장 기술 혁신의 최전선에 서서 시술의 효과, 환자의 안전, 의료 자원의 최적화를 균형 있게 실현하는 결과를 가져올 것으로 보입니다.

부문

약물 종류(β 차단제, 이뇨제, 항응고제, 기타 약물 종류별), 연령층(55세 미만, 55세 이상), 판매 채널(병원 약국, 드럭스토어·소매 약국, 온라인 프로바이더)

조사 대상 기업 사례(총 43개사)

  • 4C Medical Technologies
  • Abbott Laboratories
  • Affluent Medical
  • Anteris Technologies
  • Artivion, Inc.
  • Bayer AG
  • Boston Scientific Corporation
  • Cadrenal Therapeutics, Inc.
  • Colibri Heart Valve LLC
  • Corcym UK Limited
  • CryoLife, Inc.
  • Edwards Lifesciences Corporation
  • HighLife Medical
  • Labcor Laboratorios Ltda
  • Lepu Medical Technology Co., Ltd.
  • LivaNova PLC
  • Medtronic plc
  • Micro Interventional Devices, Inc.
  • Novartis AG
  • Zydus Lifesciences Limited

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 매출원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사하고 있습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월 : 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월 : 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역 및 관세 영향 분석:

미국 <> 중국 <> 멕시코 <> 캐나다 <> EU <> 일본 <> 인도 <> 기타 176개국

업계 최고의 이코노미스트 : Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트를 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.06.12

Global Mitral Valve Disease Therapeutics Market to Reach US$689.0 Million by 2030

The global market for Mitral Valve Disease Therapeutics estimated at US$624.9 Million in the year 2024, is expected to reach US$689.0 Million by 2030, growing at a CAGR of 1.6% over the analysis period 2024-2030. Beta Blockers, one of the segments analyzed in the report, is expected to record a 1.4% CAGR and reach US$307.9 Million by the end of the analysis period. Growth in the Diuretics segment is estimated at 1.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$170.3 Million While China is Forecast to Grow at 3.1% CAGR

The Mitral Valve Disease Therapeutics market in the U.S. is estimated at US$170.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$126.0 Million by the year 2030 trailing a CAGR of 3.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.9% CAGR.

Global Mitral Valve Disease Therapeutics Market - Key Trends & Drivers Summarized

Why Is Mitral Valve Disease Receiving Greater Clinical and Commercial Attention in Cardiovascular Therapeutics?

Mitral valve disease, encompassing conditions such as mitral regurgitation (MR) and mitral stenosis (MS), is a major contributor to global cardiovascular morbidity and mortality, particularly among aging populations. Characterized by malfunctioning of the mitral valve-which regulates blood flow between the left atrium and left ventricle-the disease leads to backflow, pressure overload, pulmonary hypertension, atrial fibrillation, and eventually heart failure if untreated. Given its progressive nature and complex pathophysiology, early diagnosis and tailored intervention are vital to prevent irreversible cardiac remodeling and death.

The burden of mitral valve disease is rising sharply in both developed and developing regions due to aging demographics, rheumatic heart disease prevalence, and improved survival from earlier cardiac interventions. Historically underdiagnosed and undertreated, mitral valve conditions are now receiving renewed attention owing to increased screening via echocardiography, greater awareness among cardiologists, and technological breakthroughs in minimally invasive therapies. This has led to an expanding therapeutic market that spans surgical repair, transcatheter valve therapy, pharmacological management, and device-based interventions.

How Are Transcatheter Interventions and Surgical Advances Transforming the Treatment Landscape?

The treatment paradigm for mitral valve disease is shifting from traditional open-heart surgery toward less invasive transcatheter approaches. Surgical mitral valve repair and replacement remain the gold standard in younger and healthier patients; however, many elderly or high-risk patients are not ideal candidates for such procedures. In this context, transcatheter mitral valve repair (TMVR) systems-such as the MitraClip (Abbott) and the PASCAL system (Edwards Lifesciences)-have revolutionized management by offering percutaneous alternatives with proven efficacy in functional and degenerative MR.

These systems enable leaflet coaptation or annuloplasty through catheter-based insertion via femoral access, significantly reducing hospitalization time, procedural risk, and recovery duration. Concurrently, pharmacotherapy-primarily comprising ACE inhibitors, beta-blockers, and diuretics-remains critical for symptom relief and management of heart failure comorbidities. Surgical innovations such as robotic-assisted valve repair, minimally invasive thoracotomy, and advanced imaging-guided intraoperative planning are further enhancing procedural precision and patient outcomes. Clinical trials are ongoing for next-generation devices that combine mitral repair with left atrial appendage closure, pulmonary vein isolation, or subvalvular interventions.

Which Patient Populations, Care Settings, and Markets Are Driving Global Adoption of Mitral Valve Therapies?

The core patient demographic for mitral valve disease therapies comprises individuals aged 65 and above, often presenting with multiple comorbidities such as hypertension, atrial fibrillation, and diabetes. Rising cardiovascular screening rates in outpatient cardiology clinics and primary care settings are increasing detection of asymptomatic or subclinical MR. Hospital-based heart teams, consisting of interventional cardiologists, cardiac surgeons, and imaging specialists, play a key role in therapeutic decision-making based on echocardiographic grading and risk stratification tools.

North America and Western Europe are leading in adoption of TMVR technologies due to favorable reimbursement systems, well-developed cardiac infrastructure, and early regulatory approvals. The Asia-Pacific region, particularly Japan and China, is witnessing rapid growth driven by increasing elderly populations, improved access to specialty cardiac care, and investment in medical device innovation. Latin America, Eastern Europe, and the Middle East are emerging markets where surgical options remain dominant, but growing interest in catheter-based therapies is beginning to reshape treatment preferences.

What Is Driving Long-Term Growth and Innovation in the Mitral Valve Disease Therapeutics Market?

The growth in the mitral valve disease therapeutics market is being fueled by the convergence of demographic trends, device innovation, clinical guideline updates, and outcome-based healthcare models. As cardiovascular care becomes increasingly personalized, the demand for less invasive, image-guided, and patient-tailored valve repair solutions is accelerating. Multi-modal imaging, machine learning for risk prediction, and integration of real-world data into therapeutic algorithms are enhancing diagnosis and procedural planning accuracy.

Payer support for TMVR procedures, expansion of TAVR (transcatheter aortic valve replacement) infrastructure to mitral applications, and cross-specialty collaboration are unlocking broader adoption. Additionally, pipeline technologies such as chordal repair systems, annuloplasty rings, and polymeric valve prostheses are diversifying the therapeutic toolkit. Pharma-device hybrid approaches-combining hemodynamic stabilization with mechanical correction-are gaining interest in heart failure-associated MR management.

As structural heart disease management evolves beyond surgical dominion, mitral valve therapeutics will remain at the forefront of cardiac innovation-delivering outcomes that balance procedural efficacy, patient safety, and healthcare resource optimization.

SCOPE OF STUDY:

The report analyzes the Mitral Valve Disease Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Beta Blockers, Diuretics, Anticoagulants, Other Drug Classes); Age Group (Below 55 Years, Above 55 Years); Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Providers)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • 4C Medical Technologies
  • Abbott Laboratories
  • Affluent Medical
  • Anteris Technologies
  • Artivion, Inc.
  • Bayer AG
  • Boston Scientific Corporation
  • Cadrenal Therapeutics, Inc.
  • Colibri Heart Valve LLC
  • Corcym UK Limited
  • CryoLife, Inc.
  • Edwards Lifesciences Corporation
  • HighLife Medical
  • Labcor Laboratorios Ltda
  • Lepu Medical Technology Co., Ltd.
  • LivaNova PLC
  • Medtronic plc
  • Micro Interventional Devices, Inc.
  • Novartis AG
  • Zydus Lifesciences Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Mitral Valve Disease Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Mitral Regurgitation and Valve Prolapse Drives Demand for Advanced Therapeutics
    • Expansion of Structural Heart Disease Programs Throws the Spotlight on Percutaneous Mitral Valve Repair Solutions
    • Advancements in Transcatheter Mitral Valve Replacement (TMVR) Propel Minimally Invasive Treatment Options
    • Growth in Aging Population and Heart Failure Cases Strengthens Business Case for Early Intervention Therapies
    • Surge in Use of Echocardiography and Cardiac MRI Enhances Early Diagnosis and Monitoring of Mitral Disease
    • Regulatory Approvals of Novel Devices Like MitraClip Drive Adoption of Non-Surgical Repair Techniques
    • Increased Investment in Valve Repair Bioprosthetics and Annuloplasty Rings Fuels Innovation in Surgical Therapies
    • Expansion of Clinical Trial Pipelines for TMVR Systems Supports Portfolio Diversification Among MedTech Companies
    • Use of Robotic-Assisted and Image-Guided Surgery Enhances Procedural Precision and Patient Outcomes
    • Growth in Hybrid Operating Rooms and Interventional Cardiology Units Supports Multi-Modality Access
    • Emphasis on Valve-in-Valve and Valve-in-Ring Technologies Strengthens Retreatment Opportunities
    • Collaborations Between Device OEMs and Academic Hospitals Accelerate Trial Enrollment and Product Refinement
    • Increasing Focus on Post-Repair Heart Function and Quality of Life Metrics Drives Demand for Durable Therapies
    • Adoption of Risk Stratification Models Enhances Patient Selection for Surgical Versus Transcatheter Approaches
    • OEM-Driven Physician Training Programs Fuel Procedural Competence and Market Penetration
    • Global Expansion of Valve Repair Expertise in Emerging Cardiology Centers Spurs Regional Growth
    • Reimbursement Frameworks and Value-Based Care Models Drive Uptake of Cost-Efficient Valve Interventions
    • Growth in Mitral Valve Repair in Low-Risk and Intermediate-Risk Patients Expands Total Treatable Population
    • Emergence of Personalized Valve Therapies Using 3D Imaging and Computational Modeling Enhances Clinical Precision
    • Device Miniaturization and Delivery System Improvements Reduce Access Challenges in High-Risk Patients
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Mitral Valve Disease Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Mitral Valve Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Mitral Valve Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Beta Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Diuretics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Below 55 Years by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Below 55 Years by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Below 55 Years by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Above 55 Years by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Above 55 Years by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Above 55 Years by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Drug Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Online Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • JAPAN
    • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • CHINA
    • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • EUROPE
    • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Mitral Valve Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Mitral Valve Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • FRANCE
    • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • GERMANY
    • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Mitral Valve Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Mitral Valve Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • INDIA
    • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Mitral Valve Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Mitral Valve Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Mitral Valve Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Mitral Valve Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • AFRICA
    • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제